The stock price of ReShape Lifesciences Inc. (NASDAQ: RSLS) has dropped by -7.85 compared to previous close of 0.17. Despite this, the company has seen a fall of -7.91% in its stock price over the last five trading days. seekingalpha.com reported 2024-08-15 that ReShape Lifesciences Inc. (NASDAQ:RSLS ) Q2 2024 Earnings Conference Call August 15, 2024 4:30 PM ET Company Participants Michael Miller – IR Paul Hickey – President and CEO Thomas Stankovich – CFO Krishna Gupta – Director, Vyome Therapeutics Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the ReShape Lifesciences Second Quarter 2024 Earnings Call.
Is It Worth Investing in ReShape Lifesciences Inc. (NASDAQ: RSLS) Right Now?
The 36-month beta value for RSLS is also noteworthy at 1.45. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RSLS is 26.74M, and at present, short sellers hold a 2.96% of that float. The average trading volume of RSLS on August 29, 2024 was 6.18M shares.
RSLS’s Market Performance
RSLS stock saw a decrease of -7.91% in the past week, with a monthly decline of -22.59% and a quarterly a decrease of -44.68%. The volatility ratio for the week is 6.39%, and the volatility levels for the last 30 days are 7.05% for ReShape Lifesciences Inc. (RSLS). The simple moving average for the past 20 days is -12.42% for RSLS’s stock, with a -23.95% simple moving average for the past 200 days.
RSLS Trading at -20.70% from the 50-Day Moving Average
After a stumble in the market that brought RSLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.99% of loss for the given period.
Volatility was left at 7.05%, however, over the last 30 days, the volatility rate increased by 6.39%, as shares sank -20.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.73% lower at present.
During the last 5 trading sessions, RSLS fell by -7.91%, which changed the moving average for the period of 200-days by -32.83% in comparison to the 20-day moving average, which settled at $0.1749. In addition, ReShape Lifesciences Inc. saw -37.97% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RSLS starting from STANKOVICH THOMAS, who sale 48 shares at the price of $0.25 back on May 31 ’24. After this action, STANKOVICH THOMAS now owns 22,777 shares of ReShape Lifesciences Inc., valued at $12 using the latest closing price.
STANKOVICH THOMAS, the Chief Financial Officer of ReShape Lifesciences Inc., sale 42 shares at $0.25 during a trade that took place back on Dec 31 ’23, which means that STANKOVICH THOMAS is holding 22,868 shares at $10 based on the most recent closing price.
Stock Fundamentals for RSLS
Current profitability levels for the company are sitting at:
- -1.15 for the present operating margin
- 0.67 for the gross margin
The net margin for ReShape Lifesciences Inc. stands at -1.12. The total capital return value is set at -2.9. Equity return is now at value -184.59, with -98.88 for asset returns.
Based on ReShape Lifesciences Inc. (RSLS), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -40.12. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is 231.55.
Currently, EBITDA for the company is -14.48 million with net debt to EBITDA at 0.1. When we switch over and look at the enterprise to sales, we see a ratio of 0.45. The receivables turnover for the company is 5.82for trailing twelve months and the total asset turnover is 1.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.90.
Conclusion
In summary, ReShape Lifesciences Inc. (RSLS) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
